Bharat Biotech's intranasal vaccine Incovacc to debut on Co-Win

Bharat Biotech said on Tuesday that it would price its intranasal Covid-19 vaccine -Incovacc - at ₹800 per dose for private markets and ₹325 for the central and state governments. The vaccine will be made available on the Co-Win platform, it said. The vaccine will be rolled out as a booster dose in the fourth week of January for those over 18 years of age.

This is the world's first intranasal vaccine for Covid-19 to receive approval for the primary 2-dose schedule, and as a heterologous booster dose.

Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) to use Incovacc as a heterologous booster.


"We have achieved the goals we set for ourselves during this pandemic. We have developed Covaxin and Incovacc , two Covid vaccines from two different platforms, with two different delivery systems," said Krishna Ella, chairman of Bharat Biotech.

"The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics," he added.

Incovacc was developed in partnership with Washington University, St. Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in preclinical studies for efficacy.

The vaccine is stable at 2-8°C for easy storage and distribution.

Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including in Gujarat, Karnataka, Maharashtra and Telangana.